GO:0070741 response to interleukin-6: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070741 (response to interleukin-6) describes any cellular or organismal process that changes state or activity in response to an interleukin-6 (IL-6) stimulus.
• IL-6 is a pleiotropic cytokine that drives immune regulation, acute-phase responses, hematopoiesis, and tumor microenvironment remodeling.
• The response to IL-6 is initiated by IL-6 binding to its receptor complex, triggering JAK-STAT3, MAPK, and PI3K-AKT signaling cascades.
• Genetic variation in IL6 and IL6R influences disease susceptibility and treatment response, as shown for rheumatoid arthritis.
• IL-6 responses are context-dependent: exercise induces myokine IL-6 secretion, while chronic elevation contributes to cancer and inflammatory disease.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect causal roles of IL-6 pathway genes in disease.
Description
GO:0070741, response to interleukin-6, is a biological process defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-6 stimulus. Interleukin-6 (IL-6) is a multifunctional cytokine produced by immune and non-immune cells that acts as a key mediator of inflammation, immunity, and hematopoiesis. The response to IL-6 is not a single linear pathway but a network of context-dependent signaling events that reprogram gene expression, metabolism, and cell fate. Understanding GO:0070741 is critical because dysregulated IL-6 responses underpin numerous human diseases, including cancer, autoimmune disorders, and inflammatory conditions. IL-6 is also a myokine released during physical activity, where its transient elevation mediates metabolic benefits. The dual nature of IL-6, protective in acute settings and pathogenic when chronic, makes precise mechanistic dissection essential. This article provides a research-grade overview of GO:0070741, covering its definition, core signaling stages, key genes, regulatory mechanisms, disease links, and state-of-the-art methods including CRISPR genome editing. All statements are grounded in published literature to support researchers studying IL-6 biology and therapeutic targeting.
response to interleukin-6 At A Glance
| GO ID | GO:0070741 |
|---|---|
| GO term | response to interleukin-6 |
| Ontology | biological_process |
| Synonym | response to IL-6 |
| Definition | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-6 stimulus. |
| Major function | Mediates cellular and systemic responses to IL-6, including immune regulation, acute-phase response, hematopoiesis, and metabolic adaptations. |
| Key signaling pathways | JAK-STAT3, MAPK/ERK, PI3K-AKT |
| Representative genes | IL6, IL6R, IL6ST, JAK1, JAK2, STAT3, SOCS3 |
| Physiological contexts | Inflammation, exercise-induced myokine response, fetal development, night-shift stress |
What Is GO:0070741?
In our own words, GO:0070741 (response to interleukin-6) encompasses all molecular, cellular, and physiological changes triggered when a cell or organism encounters interleukin-6. This includes alterations in gene expression, secretion, enzyme activity, movement, and other activities that collectively constitute the IL-6 response. The term captures both immediate signaling events and longer-term adaptive or maladaptive outcomes, such as acute-phase protein production, immune cell differentiation, and tumor microenvironment remodeling.
Why Is response to interleukin-6 Important in Cell Biology?
GO:0070741 is important because IL-6 is one of the most pleiotropic cytokines in human biology, and its response pathway is a central node in inflammation, immunity, metabolism, and cancer. Dysregulated IL-6 signaling is implicated in rheumatoid arthritis, cytokine storms, and tumor progression, making it a prime therapeutic target. Conversely, transient IL-6 elevation during exercise mediates beneficial metabolic effects, highlighting the need to distinguish acute from chronic responses. Understanding the precise molecular steps of GO:0070741 enables rational design of inhibitors, biomarkers, and CRISPR-based disease models.
• IL-6 response is a master regulator of acute-phase protein production and systemic inflammation.
• It controls immune cell differentiation, including Th17 and Treg balance, affecting autoimmunity.
• IL-6 signaling drives tumor microenvironment remodeling and immunotherapy resistance in multiple cancers.
• Genetic polymorphisms in IL6 and IL6R alter disease risk and response to DMARDs in rheumatoid arthritis.
• Exercise-induced IL-6 acts as a myokine with dose-dependent responses to physical activity duration.
• Fetal and neonatal IL-6 responses are critical for perinatal immune development and infection defense.
• IL-6 contributes to chemotherapy resistance in gastric cancer via stroma-induced signaling.
• BDNF genotype modulates IL-6 response to night-shift schedules, linking circadian stress to inflammation.
• Targeting IL-6/IL-6R is clinically validated in rheumatoid arthritis and CAR-T cytokine release syndrome.
• CRISPR screens and knockout models are essential to identify causal genes within the IL-6 response network.
What Happens During response to interleukin-6?
IL-6 Recognition and Receptor Complex Assembly
In simple terms: IL-6 binds to its receptor on the cell surface, like a key fitting a lock, to start the response.
The response to IL-6 begins when IL-6 binds to the IL-6 receptor (IL-6R, CD126). This complex then recruits the signal-transducing subunit gp130 (IL6ST), forming a hexameric signaling complex. Cells lacking membrane-bound IL-6R can still respond via soluble IL-6R in a process called trans-signaling, which expands the range of IL-6-responsive cells. Receptor assembly is the first committed step of GO:0070741 and determines downstream pathway activation.
JAK-STAT3 Activation and Transcriptional Reprogramming
In simple terms: The receptor activates JAK kinases, which turn on STAT3, a transcription factor that switches many genes on or off.
Upon receptor complex formation, constitutively associated JAK kinases (JAK1, JAK2, TYK2) phosphorylate tyrosine residues on gp130. These phosphotyrosines recruit STAT3, which is then phosphorylated by JAKs, dimerizes, and translocates to the nucleus to activate transcription of target genes including SOCS3, acute-phase proteins, and anti-apoptotic factors. This JAK-STAT3 axis is the canonical pathway of GO:0070741 and is frequently hyperactivated in cancer and autoimmune disease.
MAPK and PI3K-AKT Branch Activation
In simple terms: IL-6 also activates other signaling branches that control cell growth, survival, and metabolism.
In addition to STAT3, IL-6 triggers the MAPK/ERK and PI3K-AKT pathways via SHP2 and Gab1 recruitment to gp130. These branches regulate proliferation, survival, and metabolic reprogramming, and they can compensate when STAT3 is inhibited. In cancer, IL-6-induced MAPK and PI3K-AKT signaling contribute to tumor microenvironment remodeling and therapy resistance.
Negative Feedback and SOCS-Mediated Termination
In simple terms: The cell has brakes to stop the IL-6 response, preventing it from running out of control.
SOCS3 is a key negative feedback regulator induced by STAT3; it binds to gp130 and inhibits JAK activity, terminating the signal. Other regulators include SHP1, PIAS3, and protein tyrosine phosphatases. Loss of negative feedback leads to sustained IL-6 signaling, which is pathogenic in inflammatory diseases and cancer. The balance between activation and termination determines the magnitude and duration of GO:0070741.
Physiological and Context-Dependent Outputs
In simple terms: The final effects of IL-6 depend on the cell type and context, ranging from immune defense to metabolism.
Downstream outputs of GO:0070741 include acute-phase protein secretion by hepatocytes, Th17 differentiation, B cell maturation, and hematopoietic stem cell mobilization. In skeletal muscle, exercise induces IL-6 secretion as a myokine with dose-dependent responses to walking duration. Fetal and neonatal immune cells show distinct IL-6 response profiles critical for perinatal defense. BDNF genotype modulates IL-6 response to simulated night-shift schedules, linking circadian disruption to inflammatory outcomes.
Key Genes Involved in GO:0070741 response to interleukin-6
The following genes and proteins are central to the response to interleukin-6 (GO:0070741), spanning ligand, receptor, signaling kinases, transcription factors, and feedback regulators.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL6 | Encodes interleukin-6 cytokine; initiates the response | Target for knockout and overexpression to study inflammation and cancer |
| IL6R | IL-6 receptor alpha chain; binds IL-6 | Polymorphisms affect DMARD response in rheumatoid arthritis |
| IL6ST | gp130 signal-transducing subunit; common to IL-6 family | Essential for JAK-STAT activation; knockout is embryonic lethal |
| JAK1 | Janus kinase; phosphorylates STAT3 | Key kinase in IL-6 signaling; target for inhibitors |
| JAK2 | Janus kinase; mediates cytokine signaling | Mutations in JAK2 drive myeloproliferative neoplasms |
| STAT3 | Transcription factor; master regulator of IL-6 target genes | Constitutively active in many cancers; CRISPR KO models widely used |
| SOCS3 | Negative feedback inhibitor of JAK-STAT3 | Loss causes sustained IL-6 signaling; knockout models show inflammation |
| SHP2 (PTPN11) | Phosphatase; links gp130 to MAPK pathway | Mutations cause Noonan syndrome; regulates IL-6 branch signaling |
| PIK3CA | PI3K catalytic subunit; mediates AKT activation | IL-6-induced PI3K-AKT signaling in cancer |
| AKT1 | Serine/threonine kinase; survival signaling | Downstream of IL-6; promotes therapy resistance |
| MAPK1 (ERK2) | Kinase; mediates proliferative signals | IL-6-induced MAPK branch; target for cancer studies |
| BDNF | Neurotrophin; modulates IL-6 response to circadian stress | Genotype interacts with night-shift IL-6 response |
| CRP | Acute-phase protein; downstream of IL-6 | Biomarker of IL-6 activity in inflammation and exercise |
| TNF | Pro-inflammatory cytokine; co-regulated with IL-6 | Synergistic with IL-6 in inflammatory responses |
| IL17A | Effector cytokine of Th17 cells; induced by IL-6 | IL-6 drives Th17 differentiation in autoimmunity |
| FOXP3 | Treg transcription factor; IL-6 inhibits its activity | IL-6 modulates Treg/Th17 balance |
| VEGFA | Angiogenic factor; induced by IL-6 in tumors | IL-6 promotes angiogenesis in tumor microenvironment |
| MMP9 | Matrix metalloproteinase; IL-6-induced invasion factor | IL-6 drives metastasis in gastric cancer |
How Is response to interleukin-6 Regulated?
The response to interleukin-6 (GO:0070741) is tightly regulated at multiple levels. Negative feedback via SOCS3 is the primary intracellular brake: STAT3 induces SOCS3, which binds gp130 and inhibits JAK activity. Protein tyrosine phosphatases (SHP1, SHP2) and PIAS3 also attenuate signaling. At the receptor level, soluble gp130 can act as an antagonist of IL-6 trans-signaling, while soluble IL-6R enhances it. Epigenetic and post-transcriptional mechanisms, including microRNAs and RNA-binding proteins, further modulate IL-6 response intensity. In cancer, constitutive activation of STAT3 or loss of SOCS3 creates a feed-forward loop that sustains IL-6 signaling. Understanding these regulatory layers is essential for therapeutic targeting of GO:0070741.
response to interleukin-6 and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL6 | Rheumatoid arthritis, cytokine release syndrome, cancer | IL6 knockout mice; CRISPR KO in cancer cell lines |
| IL6R | Rheumatoid arthritis, DMARD response | IL6R point-mutation knock-in to model rs12083537 |
| STAT3 | Cancer, autoimmune disease, hyper-IgE syndrome | STAT3 knockout and constitutively active knock-in |
| SOCS3 | Inflammatory disease, cancer | SOCS3 knockout mice; overexpression in tumor cells |
| BDNF | Circadian stress, metabolic disorders | BDNF genotype knock-in models for night-shift studies |
Cancer and Tumor Microenvironment Remodeling
IL-6 is a major driver of tumor progression, where it promotes proliferation, survival, angiogenesis, and immune evasion. In gastric cancer, IL-6 secreted by stromal cells induces chemotherapy resistance, and targeting IL-6 signaling reverses this resistance. IL-6 also shapes the tumor microenvironment by recruiting immunosuppressive cells and promoting checkpoint inhibitor resistance. CRISPR knockout of IL6 or STAT3 in cancer models is widely used to validate causal roles.
Autoimmune and Inflammatory Diseases
Dysregulated IL-6 responses contribute to rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus. Polymorphisms in IL6 (rs1800795) and IL6R (rs12083537) are associated with differential response to disease-modifying antirheumatic drugs in rheumatoid arthritis. Tocilizumab, an IL-6R antagonist, is clinically approved for several autoimmune conditions, validating GO:0070741 as a therapeutic target.
Exercise, Metabolism, and Circadian Stress
IL-6 is released from skeletal muscle during exercise as a myokine, with dose-dependent increases related to walking duration. Ultramarathon running induces a robust inflammatory response involving IL-6, CRP, and TNF-alpha. Simulated night-shift schedules also elevate IL-6, and this response is modulated by BDNF genotype, linking circadian disruption to inflammatory risk. These contexts highlight the adaptive versus maladaptive faces of GO:0070741.
Perinatal and Neonatal Immunity
Fetal and early neonatal immune systems exhibit distinct IL-6 response patterns that are critical for defense against infection and for shaping immune development. Dysregulated IL-6 signaling in neonates is associated with sepsis and inflammatory complications. Understanding GO:0070741 in this context informs pediatric therapeutic strategies.
From response to interleukin-6-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL6 loss reduce tumor growth? | IL6 knockout cancer cell lines and xenografts |
| How does IL6R polymorphism affect drug response? | IL6R point-mutation knock-in in primary immune cells |
| What is the role of STAT3 in IL-6-driven transcription? | STAT3 knockout with RNA-seq and ChIP-seq |
| Can SOCS3 overexpression terminate chronic IL-6 signaling? | SOCS3 overexpression in inflammatory cell models |
| How does exercise-induced IL-6 affect metabolism? | IL6 knockout mice subjected to exercise protocols |
| Does BDNF genotype modulate IL-6 response to circadian stress? | BDNF knock-in mice under simulated night-shift schedules |
How to Study the response to interleukin-6 Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Transcriptional profiling of IL-6 response |
| Phosphoproteomics | Phosphorylation of signaling proteins | Mapping JAK-STAT, MAPK, AKT activation |
| Single-cell RNA-seq | Cell-to-cell heterogeneity | Tumor microenvironment IL-6 responses |
| CRISPR knockout screen | Genes required for IL-6 phenotypes | Identifying resistance and survival factors |
| ChIP-seq | STAT3 DNA binding sites | Identifying direct IL-6 target genes |
| ELISA | Secreted IL-6, CRP, TNF-alpha levels | Exercise and inflammatory studies |
| Live-cell imaging | STAT3 nuclear translocation dynamics | Single-cell signaling kinetics |
| Flow cytometry | Immune cell differentiation (Th17/Treg) | IL-6-driven T cell polarization |
Transcriptomic Profiling of IL-6 Response
RNA-seq after IL-6 stimulation reveals the full set of genes whose expression changes during GO:0070741. Time-course experiments capture immediate early (STAT3 targets) and delayed (secondary) responses. In cancer models, RNA-seq of IL-6-treated versus untreated cells identifies resistance pathways. CRISPR knockout of candidate genes followed by RNA-seq validates their contribution to the transcriptional program.
Proteomic and Phosphoproteomic Analysis
Mass spectrometry-based phosphoproteomics maps the rapid phosphorylation events triggered by IL-6, including JAK, STAT3, MAPK, and AKT activation. Proteomics of secreted proteins identifies acute-phase proteins and cytokines released during the response. These methods provide a global view of signaling dynamics in GO:0070741.
Imaging and Single-Cell Approaches
Live-cell imaging of STAT3 nuclear translocation using fluorescent reporters visualizes IL-6 response at single-cell resolution. Single-cell RNA-seq reveals heterogeneity in IL-6 responses across cell populations, important for understanding tumor microenvironment remodeling. These techniques capture the spatiotemporal dynamics of GO:0070741.
Functional Genomics and CRISPR Screens
Genome-wide CRISPR knockout screens identify genes required for IL-6-induced phenotypes, such as survival or drug resistance. Pooled screens with IL-6 stimulation uncover positive and negative regulators of the pathway. These functional genomics approaches are powerful for discovering new components of GO:0070741.
How CRISPR Can Be Used to Study GO:0070741 response to interleukin-6
Knockout
CRISPR knockout of IL6, IL6R, STAT3, or SOCS3 in cell lines and primary cells is used to determine their causal roles in GO:0070741. For example, STAT3 knockout abolishes IL-6-induced transcription, while SOCS3 knockout prolongs signaling. In cancer models, IL6 knockout reduces tumor growth and reverses chemotherapy resistance. These models are essential for target validation.
Point Mutation
CRISPR point mutation introduces disease-associated variants, such as IL6 rs1800795 or IL6R rs12083537, to study their functional impact on IL-6 response and drug sensitivity. Base editing and prime editing enable precise single-nucleotide changes without double-strand breaks. These models help explain inter-individual differences in GO:0070741.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) into IL6 or STAT3 loci allows real-time monitoring of expression and localization during the IL-6 response. Knock-in of constitutively active STAT3 mutants models chronic IL-6 signaling in cancer. These approaches provide spatial and temporal resolution of GO:0070741.
Overexpression
CRISPR-mediated overexpression of IL6, SOCS3, or dominant-negative STAT3 enables gain-of-function studies. Overexpression of IL6 in tumor cells promotes angiogenesis and immune evasion, modeling the tumor microenvironment. SOCS3 overexpression suppresses IL-6 signaling, validating negative feedback. These models complement knockout studies for a complete picture of GO:0070741.
How EDITGENE Supports response to interleukin-6 Research
Researchers studying response to interleukin-6-related genes often need to determine whether a candidate gene is causally involved in IL-6 signaling, disease progression, or therapeutic response. EDITGENE provides end-to-end CRISPR solutions, from knockout and point-mutation models to knock-in reporters, overexpression lines, and genome-wide library screening, enabling rigorous functional dissection of GO:0070741 in any cell type.
Contact EDITGENE today to design your custom CRISPR model for response to interleukin-6 research.
Frequently Asked Questions About response to interleukin-6
What is GO:0070741 response to interleukin-6?
GO:0070741 is a Gene Ontology biological process term defined as any process that results in a change in state or activity of a cell or an organism as a result of an interleukin-6 stimulus, including changes in gene expression, secretion, movement, and enzyme production.
What genes are involved in response to interleukin-6?
Key genes include IL6, IL6R, IL6ST (gp130), JAK1, JAK2, STAT3, SOCS3, and downstream effectors such as CRP and MMP9.
How does IL-6 signaling work?
IL-6 binds to IL-6R, recruits gp130, activates JAK kinases, and phosphorylates STAT3, which dimerizes and translocates to the nucleus to regulate target genes; MAPK and PI3K-AKT branches are also activated.
What diseases are associated with IL-6 response?
Dysregulated IL-6 responses are linked to rheumatoid arthritis, cancer, inflammatory bowel disease, cytokine release syndrome, and metabolic disorders.
Can CRISPR be used to study IL-6 signaling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect causal roles of IL-6 pathway genes in disease and therapy response.
What is the role of IL-6 in exercise?
IL-6 is released from skeletal muscle during exercise as a myokine, with dose-dependent increases related to walking duration, and it contributes to metabolic adaptations.
How is IL-6 response regulated?
SOCS3 provides negative feedback by inhibiting JAK activity; phosphatases, PIAS3, and soluble receptors also modulate the response.
What is the link between IL-6 and cancer?
IL-6 promotes tumor proliferation, survival, angiogenesis, and immune evasion, and it contributes to chemotherapy resistance in cancers such as gastric cancer.
Does genotype affect IL-6 response?
Yes, polymorphisms in IL6 and IL6R are associated with differential response to rheumatoid arthritis drugs, and BDNF genotype modulates IL-6 response to night-shift schedules.
What methods are used to study response to interleukin-6?
Common methods include RNA-seq, phosphoproteomics, single-cell RNA-seq, CRISPR screens, ChIP-seq, ELISA, and live-cell imaging.
Conclusion
GO:0070741 (response to interleukin-6) is a central biological process that governs immune regulation, inflammation, metabolism, and cancer progression. Its complexity, spanning receptor assembly, JAK-STAT3 activation, MAPK/PI3K branches, and negative feedback, requires sophisticated experimental models to dissect. CRISPR-based knockout, point mutation, knock-in, and overexpression approaches, combined with functional genomics and bioinformatics, provide the tools needed to identify causal genes and therapeutic targets. As IL-6-targeted therapies expand, understanding the precise mechanisms of GO:0070741 will remain essential for translational research.
References
- 1. Wu S et al.. 2025. Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy.. Cytokine Growth Factor Rev 85:93-102 PMID: 39828476
- 2. Tanaka T et al.. 2016. Regulation of IL-6 in Immunity and Diseases.. Adv Exp Med Biol 941:79-88 PMID: 27734409
- 3. Lee YH et al.. 2022. Associations between the interleukin-6 rs1800795 G/C and interleukin-6 receptor rs12083537 A/G polymorphisms and response to disease-modifying antirheumatic drugs in rheumatoid arthritis: A meta-analysis.. Int Immunopharmacol 112:109184 PMID: 36058033
- 4. Waśkiewicz Z et al.. 2025. Inflammatory Response to Ultramarathon Running: A Review of IL-6, CRP, and TNF-α.. Int J Mol Sci 26(13) PMID: 40650093
- 5. Satterfield BC et al.. 2020. Interleukin-6 (IL-6) response to a simulated night-shift schedule is modulated by brain-derived neurotrophic factor (BDNF) genotype.. Chronobiol Int 37(9-10):1452-1456 PMID: 32819178
- 6. Chiesa C et al.. 2015. Fetal and early neonatal interleukin-6 response.. Cytokine 76(1):1-12 PMID: 25890877
- 7. Ham IH et al.. 2019. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer.. Mol Cancer 18(1):68 PMID: 30927911
- 8. Kistner TM et al.. 2024. Myokine secretion during moderate-intensity physical activity: Dose-response of interleukin 6 to walking duration.. Am J Hum Biol 36(10):e24131 PMID: 39030918
